Eccentric treadmill training and skeletal muscle immunometabolic responses in HFD-induced insulin resistance
Abstract
Introduction In recent years, repeated eccentric exercise has gained increasing attention as a potentially superior intervention for ameliorating insulin resistance (IR). However, the underlying mechanisms responsible for these effects remain incompletely understood. This study aims to investigate the effects and underlying mechanisms of moderate-intensity eccentric treadmill training on skeletal muscle IR. Methods A mouse model of IR was established using a high-fat diet (HFD) for 12 weeks, followed by an 8-week eccentric treadmill training. In vitro , RAW264.7 macrophages under high-glucose conditions were treated with the AKT agonist SC79 or inhibitor MK2206. Comprehensive assessments included protein localization and expression (immunofluorescence, Western blot), macrophage polarization status (flow cytometry), inflammatory infiltration (H&E staining), cytokine profiles (ELISA), and cellular viability (CCK-8). Results HFD-induced IR led to elevated pro-inflammatory factors and reduced GLUT4, F4/80 & phospho-AKT (Ser 473 ) co-localization, IL-10, and Arg-1 levels, all of which were significantly reversed by eccentric training. In vitro , high glucose reduced the phospho-AKT (Ser 473 )/AKT ratio, while SC79 suppressed an M1-like pro- inflammatory phenotype, as indicated by decreased iNOS and F4/80&CD86 double-positive rates and increased Arg-1 and F4/80&CD206 double-positive rates. These effects were abolished by MK2206. Conclusion Moderate-intensity eccentric treadmill training ameliorates HFD-induced skeletal muscle IR, likely driven by AKT-mediated reduction in pro-inflammatory M1 macrophage polarization.
Fields of Study & Subjects
Exercise and Physiological Responses
Adipokines
Inflammation
and Metabolic Diseases
Adipose Tissue and Metabolism
Publication details
- Journal / source
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Volume
- 17
- Pages
- 1757925–1757925
- Publication date
- 25 February 2026
- Language
- EN